Onco3R Therapeutics

At onco3R, we take a modality-agnostic R&D strategy to unlock the full therapeutic potential of clinically validated targets. Our pipeline includes both small molecules and antibody-based therapies, each tailored to adress the complex disease biology in oncology and immunology.